GNQWFI

GNQWFI, an anti-Flt1 peptide, is a VEGFR1-specific antagonist. GNQWFI blocks the interaction of VEGFR1 with various VEGFR1 ligands, such as VEGFA, VEGFB, and placental growth factor (PIGF) and inhibits VEGF-induced endothelial cell migration and tube formation. GNQWFI is promising for research of cancer, asthma, and other ocular diseases[1].

Product Specifications

CAS Number

[853995-60-5]

UNSPSC

12352209

Target

VEGFR

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Cardiovascular Disease

Purity

99.45

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

CC[C@H](C)[C@@H](C(O)=O)NC([C@H](CC1=CC=CC=C1)NC([C@@H](NC([C@H](CCC(N)=O)NC([C@H](CC(N)=O)NC(CN)=O)=O)=O)CC2=CNC3=CC=CC=C23)=O)=O

Molecular Formula

C37H49N9O9

Molecular Weight

763.84

References & Citations

[1]Oh EJ, et al. Synthesis, characterization, and preliminary assessment of anti-Flt1 peptide-hyaluronate conjugate for the treatment of corneal neovascularization. Biomaterials. 2009 Oct;30 (30) :6026-34.